DE69421835T2 - Die Verwendung von Erythropoetin für die Herstellung einer pharmazeutischen Zubereitung für pulmonare Verabreichung oder Inhalation. - Google Patents

Die Verwendung von Erythropoetin für die Herstellung einer pharmazeutischen Zubereitung für pulmonare Verabreichung oder Inhalation.

Info

Publication number
DE69421835T2
DE69421835T2 DE69421835T DE69421835T DE69421835T2 DE 69421835 T2 DE69421835 T2 DE 69421835T2 DE 69421835 T DE69421835 T DE 69421835T DE 69421835 T DE69421835 T DE 69421835T DE 69421835 T2 DE69421835 T2 DE 69421835T2
Authority
DE
Germany
Prior art keywords
erythropoietin
inhalation
pulmonary administration
manufacture
pharmaceutical preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69421835T
Other languages
English (en)
Other versions
DE69421835T3 (de
DE69421835D1 (de
Inventor
Colin G Pitt
Robert M Platz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21760356&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69421835(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of DE69421835D1 publication Critical patent/DE69421835D1/de
Application granted granted Critical
Publication of DE69421835T2 publication Critical patent/DE69421835T2/de
Publication of DE69421835T3 publication Critical patent/DE69421835T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
DE69421835T 1993-02-04 1994-02-02 Die Verwendung von Erythropoetin für die Herstellung einer pharmazeutischen Zubereitung für pulmonare Verabreichung oder Inhalation. Expired - Lifetime DE69421835T3 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/013,514 US5354934A (en) 1993-02-04 1993-02-04 Pulmonary administration of erythropoietin

Publications (3)

Publication Number Publication Date
DE69421835D1 DE69421835D1 (de) 2000-01-05
DE69421835T2 true DE69421835T2 (de) 2000-05-18
DE69421835T3 DE69421835T3 (de) 2003-12-24

Family

ID=21760356

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69421835T Expired - Lifetime DE69421835T3 (de) 1993-02-04 1994-02-02 Die Verwendung von Erythropoetin für die Herstellung einer pharmazeutischen Zubereitung für pulmonare Verabreichung oder Inhalation.

Country Status (14)

Country Link
US (1) US5354934A (de)
EP (1) EP0613683B2 (de)
JP (1) JP4338214B2 (de)
AT (1) ATE187061T1 (de)
AU (1) AU677378B2 (de)
CA (1) CA2155334C (de)
DE (1) DE69421835T3 (de)
DK (1) DK0613683T4 (de)
ES (1) ES2139678T5 (de)
GR (1) GR3032374T3 (de)
HK (1) HK1009239A1 (de)
IL (1) IL108528A (de)
WO (1) WO1994017784A1 (de)
ZA (1) ZA94737B (de)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE76311T1 (de) 1986-08-19 1992-06-15 Genentech Inc Einrichtung und dispersion zum intrapulmonalen eingeben von polypeptidwuchsstoffen und zytokinen.
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5661125A (en) * 1992-08-06 1997-08-26 Amgen, Inc. Stable and preserved erythropoietin compositions
US6012450A (en) * 1993-01-29 2000-01-11 Aradigm Corporation Intrapulmonary delivery of hematopoietic drug
US6051256A (en) * 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
KR100419037B1 (ko) 1994-03-07 2004-06-12 넥타르 테라퓨틱스 폐를통한인슐린의전달방법및그조성물
CA2190502A1 (en) 1994-05-18 1995-11-23 Robert M. Platz Methods and compositions for the dry powder formulation of interferons
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US6586006B2 (en) 1994-08-04 2003-07-01 Elan Drug Delivery Limited Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
IL116085A (en) * 1994-12-16 1999-12-31 Ortho Pharma Corp Spray dried erythropoietin
US6485726B1 (en) 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
WO1996030068A1 (en) 1995-03-31 1996-10-03 Aradigm Corporation Intrapulmonary delivery of hematopoietic drug
AU706195B2 (en) * 1995-04-14 1999-06-10 Inhale Therapeutic Systems Powdered pharmaceutical formulations having improved dispersibility
US5869451A (en) 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
NZ310778A (en) 1995-06-07 1999-10-28 Glaxo Group Ltd Peptides and compounds that bind to a thrombopoietin receptor
DE19539574A1 (de) * 1995-10-25 1997-04-30 Boehringer Mannheim Gmbh Zubereitungen und Verfahren zur Stabilisierung biologischer Materialien mittels Trocknungsverfahren ohne Einfrieren
US5875776A (en) * 1996-04-09 1999-03-02 Vivorx Pharmaceuticals, Inc. Dry powder inhaler
ATE247948T1 (de) * 1996-04-29 2003-09-15 Dura Pharma Inc Verfahren zum inhalieren trockener pulver
US7091311B2 (en) 1996-06-07 2006-08-15 Smithkline Beecham Corporation Peptides and compounds that bind to a receptor
GB9612297D0 (en) * 1996-06-11 1996-08-14 Minnesota Mining & Mfg Medicinal aerosol formulations
US5952226A (en) * 1996-11-05 1999-09-14 Modex Therapeutiques Hypoxia responsive EPO producing cells
US20030203036A1 (en) 2000-03-17 2003-10-30 Gordon Marc S. Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
GB9703673D0 (en) * 1997-02-21 1997-04-09 Bradford Particle Design Ltd Method and apparatus for the formation of particles
DE19733651A1 (de) * 1997-08-04 1999-02-18 Boehringer Ingelheim Pharma Wässrige Aerosolzubereitungen enthaltend biologisch aktive Markomoleküle und Verfahren zur Erzeugung entsprechender Aerosole
US6946117B1 (en) 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
KR100572171B1 (ko) † 1997-09-29 2006-04-19 넥타르 테라퓨틱스 투여량 계측 흡입기용 안정화 제제
US6696411B1 (en) 1998-04-22 2004-02-24 Cornell Research Foundation, Inc. Canine erythropoietin gene and recombinant protein
JP2002512039A (ja) * 1998-04-22 2002-04-23 コーネル リサーチ ファンデーション インク． イヌエリスロポエチン遺伝子および組換えタンパク質
JP2003523940A (ja) * 1999-05-11 2003-08-12 オーソ−マクネイル ファーマシューティカル インコーポレイテッド エリスロポエチン投与の薬物速度論的および薬力学的モデリング
US7332275B2 (en) 1999-10-13 2008-02-19 Sequenom, Inc. Methods for detecting methylated nucleotides
WO2001036604A2 (en) 1999-11-18 2001-05-25 Corvas International, Inc. Nucleic acids encoding endotheliases, endotheliases and uses thereof
IL150461A0 (en) * 1999-12-30 2002-12-01 Chiron Corp Methods for pulmonary delivery of interleukin-2
US7700341B2 (en) 2000-02-03 2010-04-20 Dendreon Corporation Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
PT1280520E (pt) 2000-05-10 2014-12-16 Novartis Ag Pós à base de fosfolípidos para administração de fármacos
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
DE60109625T3 (de) * 2000-05-15 2017-08-03 F. Hoffmann-La Roche Ag Flüssige arzneizubereitung enthaltend ein erythropoietin derivat
US7575761B2 (en) 2000-06-30 2009-08-18 Novartis Pharma Ag Spray drying process control of drying kinetics
GB0027357D0 (en) 2000-11-09 2000-12-27 Bradford Particle Design Plc Particle formation methods and their products
KR100587237B1 (ko) * 2000-11-29 2006-06-07 이토햄 가부시키가이샤 분말제제 및 그의 제조방법
US7767643B2 (en) 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
RU2317086C2 (ru) * 2001-02-02 2008-02-20 Орто-Макнейл Фармасьютикал, Инк. Лечение неврологической дисфункции с применением сульфаматов фруктопиранозы и эритропоэтина
US20030072717A1 (en) * 2001-02-23 2003-04-17 Vapotronics, Inc. Inhalation device having an optimized air flow path
AU2002305052A1 (en) 2001-03-13 2002-09-24 Corvas International, Inc. Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon
GB0107106D0 (en) * 2001-03-21 2001-05-09 Boehringer Ingelheim Pharma Powder inhaler formulations
WO2002077263A2 (en) 2001-03-22 2002-10-03 Dendreon San Diego Llc Nucleic acid molecules encoding serine protease cvsp14, the encoded polypeptides and methods based thereon
CA2448022C (en) * 2001-05-21 2013-11-12 Injet Digital Aerosols Limited Compositions for protein delivery via the pulmonary route
EG24184A (en) * 2001-06-15 2008-10-08 Otsuka Pharma Co Ltd Dry powder inhalation system for transpulmonary
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
SI1458360T1 (sl) 2001-12-19 2011-08-31 Novartis Ag Pulmonalno dajanje aminoglikozidov
WO2003055526A2 (en) * 2001-12-21 2003-07-10 Maxygen Aps Erythropoietin conjugates
US7582284B2 (en) 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
GB0216562D0 (en) 2002-04-25 2002-08-28 Bradford Particle Design Ltd Particulate materials
US7432342B2 (en) 2002-05-03 2008-10-07 Sequenom, Inc. Kinase anchor protein muteins, peptides thereof and related documents
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
US20040009908A1 (en) * 2002-07-10 2004-01-15 Stamler Jonathan S. Methods for treating or preventing ischemic injury
DE10234192B4 (de) 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
DE10234165B4 (de) * 2002-07-26 2008-01-03 Advanced Micro Devices, Inc., Sunnyvale Verfahren zum Füllen eines Grabens, der in einem Substrat gebildet ist, mit einem isolierenden Material
ES2781475T3 (es) 2002-09-18 2020-09-02 Janssen Pharmaceuticals Inc Métodos para aumentar la producción de células madre hematopoyéticas y plaquetas
EP1852441B1 (de) 2002-09-24 2012-03-28 The Burnham Institute Mittel zur Modulierung der EPH-Rezeptor-Aktivität
EP1575562B1 (de) * 2002-11-26 2016-10-05 Seacoast Neurosciene, Inc. Schwimmfähige, therapeutika freigebende polymerteilchen
US20040132645A1 (en) * 2003-01-03 2004-07-08 Knox Susan J. Methods for modulating effects of radiation in a subject
EP1596854A4 (de) 2003-02-14 2007-06-06 Childrens Hosp & Res Ct Oak Behandlung von erkrankungen im zusammenhang mit verringerter stickoxid-bioverfügbarkeit, einschliesslich erhöhte arginase
AU2004229465B2 (en) * 2003-04-09 2010-04-29 The United States Of America Department Of Veterans Affairs Compositions and methods related to production of erythropoietin
DE102004063927A1 (de) * 2004-01-23 2005-12-15 Epoplus Gmbh Co.Kg Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden
US7714114B2 (en) * 2005-02-16 2010-05-11 Nektar Therapeutics Conjugates of an EPO moiety and a polymer
US8000981B2 (en) 2005-11-30 2011-08-16 The Invention Science Fund I, Llc Methods and systems related to receiving nutraceutical associated information
US10296720B2 (en) 2005-11-30 2019-05-21 Gearbox Llc Computational systems and methods related to nutraceuticals
US7827042B2 (en) 2005-11-30 2010-11-02 The Invention Science Fund I, Inc Methods and systems related to transmission of nutraceutical associated information
US8340944B2 (en) 2005-11-30 2012-12-25 The Invention Science Fund I, Llc Computational and/or control systems and methods related to nutraceutical agent selection and dosing
US7927787B2 (en) 2006-06-28 2011-04-19 The Invention Science Fund I, Llc Methods and systems for analysis of nutraceutical associated components
US20080210748A1 (en) 2005-11-30 2008-09-04 Searete Llc, A Limited Liability Corporation Of The State Of Delaware, Systems and methods for receiving pathogen related information and responding
US7974856B2 (en) 2005-11-30 2011-07-05 The Invention Science Fund I, Llc Computational systems and methods related to nutraceuticals
US8297028B2 (en) 2006-06-14 2012-10-30 The Invention Science Fund I, Llc Individualized pharmaceutical selection and packaging
AR060522A1 (es) * 2006-04-19 2008-06-25 Alba Therapeutics Corp Uso de agonistas de uniones apretadas para facilitar la entrega pulmonar de agentes terapeuticos
EP2046951B1 (de) 2006-07-05 2011-10-26 Catalyst Biosciences, Inc. Protease-screening-verfahren und dadurch identifizierte proteasen
PL2425820T3 (pl) 2007-02-11 2015-08-31 Map Pharmaceuticals Inc Sposób terapeutycznego stosowania dhe w celu umożliwienia szybkiego złagodzenia migreny przy jednoczesnym zminimalizowaniu profilu działań niepożądanych
TW201803586A (zh) 2008-08-14 2018-02-01 艾瑟勒朗法瑪公司 使用ｇｄｆ阱以增加紅血球水平
US9808030B2 (en) 2011-02-11 2017-11-07 Grain Processing Corporation Salt composition
BR112014009528B1 (pt) * 2011-10-17 2020-12-29 Acceleron Pharma, Inc. usos de polipeptídeos actriib para a fabricação de um medicamento para tratar eritropoiese ineficaz
KR102052983B1 (ko) 2012-01-26 2019-12-06 크리스토퍼 제이. 소레스 펩타이드 호르몬의 칼시토닌 cgrp 패밀리의 펩타이드 길항제 및 그의 용도
US20140350087A9 (en) 2012-03-22 2014-11-27 Halozyme, Inc. Oncovector Nucleic Acid Molecules and Methods of Use
WO2015136527A1 (en) 2014-03-10 2015-09-17 Health Corporation - Rambam Heparanase inhibitory peptides and use thereof for treating clinical pathologies
US20180050005A1 (en) 2016-08-16 2018-02-22 Janssen Pharmaceutica Nv Concentrated Solution of 17-Hydroxydocosahexaenoic Acid
EP4316595A3 (de) 2016-09-02 2024-04-17 Christopher J. Soares Verwendung von cgrp-rezeptor-antagonisten bei der behandlung des glaukoms
EP3658191A1 (de) 2017-07-26 2020-06-03 Janssen Pharmaceutica NV Verfahren zum schutz der gefässintegrität durch gezielte strahlentherapie
AU2020211412A1 (en) 2019-01-25 2021-08-12 Janssen Pharmaceutica Nv Methods for mitigating liver injury and promoting liver hypertrophy, regeneration and cell engraftment in conjunction with radiation and/or radiomimetic treatments
MA54821A (fr) 2019-01-25 2021-12-01 Janssen Pharmaceutica Nv Méthodes pour augmenter la protection contre les lésions des organes et des vaisseaux, la récupération hématopoïétique et la survie en réponse à une exposition à une irradiation corporelle totale ou à des agents chimiques
KR20210120037A (ko) 2019-01-25 2021-10-06 잔센파마슈티카엔.브이. 수포제 및 가성 가스의 독성 영향 경감 방법
EP3946417A1 (de) 2019-03-29 2022-02-09 Pieris Pharmaceuticals GmbH Inhalierte verabreichung von lipocalin-muteinen
BR112022001185A2 (pt) 2019-08-01 2022-03-15 Acm Biolabs Pte Ltd Método de eliciamento de uma resposta imune administrando uma população de polimerossomos tendo um antígeno associado com uma população de polimerossomos tendo um adjuvante associado, bem como composições compreendendo as duas populações de polimerossomos
EP4138899A2 (de) 2020-04-24 2023-03-01 ACM Biolabs Pte Ltd Impfstoff gegen humane pathogene coronaviren
JP2024500360A (ja) 2020-12-11 2024-01-09 エイシーエム バイオラブズ プライベート リミテッド 関連づけられた抗原および関連づけられたアジュバントを有する２つのポリマーソーム集団を投与することによる、Ｔｈ１／Ｔｈ２免疫応答の調整方法
WO2022167497A1 (en) 2021-02-02 2022-08-11 Acm Biolabs Pte Ltd Sole use of polymersome associated adjuvant for stimulating an immune response
EP4320141A1 (de) 2021-04-08 2024-02-14 Pieris Pharmaceuticals GmbH Neue für den bindegewebewachstumsfaktor (ctgf) spezifische lipocalinmuteine
CA3234340A1 (en) 2021-10-01 2023-04-06 Janssen Pharmaceutica N.V. Methods of increasing progenitor cell production
WO2023168426A1 (en) 2022-03-03 2023-09-07 Enosi Therapeutics Corporation Compositions and cells containing mixtures of oligo-trap fusion proteins (ofps) and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1575050A1 (de) 1966-01-12 1972-04-13 Misto Gen Equipment Co Ultraschall-Nebelerzeugungsgeraet
JPS59163313A (ja) † 1983-03-09 1984-09-14 Teijin Ltd 経鼻投与用ペプチドホルモン類組成物
US4703008A (en) * 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
US4635627A (en) * 1984-09-13 1987-01-13 Riker Laboratories, Inc. Apparatus and method
GB2177914B (en) * 1985-06-04 1989-10-25 Chugai Pharmaceutical Co Ltd A pharmaceutical composition containing human erythropoietin and a surface active agent for nasal administration for the treatment of anemia
ATE76311T1 (de) † 1986-08-19 1992-06-15 Genentech Inc Einrichtung und dispersion zum intrapulmonalen eingeben von polypeptidwuchsstoffen und zytokinen.
US5013718A (en) * 1986-11-21 1991-05-07 Amgen, Inc. Method for treating iron overload using EPO
JP2656944B2 (ja) † 1987-04-30 1997-09-24 クーパー ラボラトリーズ タンパク質性治療剤のエアロゾール化
ZA887658B (en) * 1987-10-15 1990-06-27 Syntex Inc Intranasal administration of polypeptides in powdered form
US5011678A (en) * 1989-02-01 1991-04-30 California Biotechnology Inc. Composition and method for administration of pharmaceutically active substances
JPH05963A (ja) * 1990-04-13 1993-01-08 Toray Ind Inc ポリペプチド類組成物
US5469750A (en) 1991-03-05 1995-11-28 Aradigm Corporation Method and apparatus for sensing flow in two directions and automatic calibration thereof
WO1992016192A1 (en) * 1991-03-15 1992-10-01 Amgen Inc. Pulmonary administration of granulocyte colony stimulating factor
GB9116610D0 (en) † 1991-08-01 1991-09-18 Danbiosyst Uk Preparation of microparticles
EP0621774B1 (de) † 1992-01-21 1996-12-18 Sri International Verbessertes verfahren zur herstellung von mikronisierter polypeptidarzneimitteln
US5626871A (en) † 1992-06-12 1997-05-06 Teijin Limited Preparation for intratracheobronchial administration

Also Published As

Publication number Publication date
CA2155334C (en) 2006-08-15
ES2139678T3 (es) 2000-02-16
JP4338214B2 (ja) 2009-10-07
ZA94737B (en) 1994-09-29
JPH08507753A (ja) 1996-08-20
HK1009239A1 (en) 1999-05-28
EP0613683A1 (de) 1994-09-07
IL108528A0 (en) 1994-05-30
US5354934A (en) 1994-10-11
DK0613683T3 (da) 2000-04-03
ATE187061T1 (de) 1999-12-15
DE69421835T3 (de) 2003-12-24
IL108528A (en) 1999-05-09
DE69421835D1 (de) 2000-01-05
EP0613683B2 (de) 2003-06-04
AU6098794A (en) 1994-08-29
EP0613683B1 (de) 1999-12-01
GR3032374T3 (en) 2000-04-27
AU677378B2 (en) 1997-04-24
CA2155334A1 (en) 1994-08-18
DK0613683T4 (da) 2003-07-14
WO1994017784A1 (en) 1994-08-18
ES2139678T5 (es) 2003-12-01

Similar Documents

Publication Publication Date Title
ATE187061T1 (de) Die verwendung von erythropoetin für die herstellung einer pharmazeutischen zubereitung für pulmonare verabreichung oder inhalation.
ATE77557T1 (de) Zusammensetzung zur erhoehung der intrazell-atpspiegel und des physischen leistungsniveaus und zur erhoehung der geschwindigkeit von wundenheilung.
ATE103914T1 (de) Neue thienylcarbonsaeureester von aminoalkoholen, ihre quaternierungsprodukte sowie die herstellung und verwendung dieser verbindungen.
ATE124253T1 (de) Verwendung von pharmazeutischen und kosmetischen präparaten mit mischmicellen.
DE3785684T2 (de) Pyrrolidinamid-Derivate von Acylaminosäure, pharmazeutische Zusammensetzung und Verwendung.
DE3855113T2 (de) Verwendung von Buspiron zur Herstellung eines pharmazeutischen Präparats zur Behandlung der Alkoholsucht
ATE100320T1 (de) Verwendung von thromboxan-a2-rezeptorantagonisten zur herstellung einer pharmazeutischen zusammensetzung zur behandlung von hautkrankheiten.
DE3781182T2 (de) Tamoxifen zur topischen verwendung.
DE3850154T2 (de) Verwendung von Gepiron zur Herstellung eines pharmazeutischen Präparats zur Behandlung atypischer Depression.
ATE70441T1 (de) Vitaminhaltiges mittel zur behandlung und zum schutz der schleimhaeute sowie verwendung von vitamin e zur herstellung des mittels.
ATE79254T1 (de) Die verwendung von d-fenfluramin zur herstellung von arzneimitteln, zur behandlung von depressionen.
EP0018668A3 (de) Mittel zur mechanischen Entfernung von Körperhaaren
Kosten et al. Bromocriptine treatment of cocaine abuse in patients maintained on methadone.
JPS6416890A (en) Antioxidant
ES2037807T3 (es) Medicamentos que contienen en combinacion interferon y 1-desoxi-piperidinosas, procedimiento para su fabricacion y su aplicacion.
DK277387D0 (da) Terapeutisk topikal sammensaetning mod en hyperprolifererende epithelsygdom
Axelsson et al. Relationship between serum concentrations of thioridazine and its main nonconjugated metabolites and the clinical response in thioridazine-treated patients.
DE3650368T2 (de) Verwendung von Depogen zur Behandlung von eingeschränktem Blutkreislauf.
DE3667472D1 (de) Analoge von hypokalzemischen polypeptiden, welche den kalziumgehalt des koerpers schonen, deren herstellung, deren verwendung als arznei und diese enthaltende zusammensetzungen.
DE319316T1 (de) Monoester von griseolsaeure, ihre herstellung und verwendung.
ATE122563T1 (de) Verwendung von 15-keto-prostansäure-derivaten zur herstellung eines medikaments für die verbesserung der ausscheidung des kaliumions.
Renik The clinical use of the manifest dream.
ATE65396T1 (de) Verwendung von carbonsaeure in fuer topische anwendung vorgesehenen pharmazeutischen zubereitungen.
Ashkinazi Functional deficiency of erythrocyte thromboplastin factor
DE3687448D1 (de) Verwendung von 6h-7,8-dihydrothiapyrano(3,2d)pyrimidinen zur herstellung von arzneimitteln zur verwendung als hypoglykaemische mittel oder als abmagerungsmittel fuer fettsuechtige patienten.

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings